Understanding the Forward Muon Deficit in Coherent Pion Production

For any inelastic process $v_{\ell} + I \to \ell^- + F$ with $m_{\ell} = 0$, the cross section at $\theta_{\ell} = 0$ is given by Adler's PCAC theorem. Inclusion of the lepton mass has a dynamical effect (``PCAC-screening'') caused by interference of spin-zero ($\pi^+$) and spin-one exchanges. This effect may be relevant to the forward suppression reported in recent experiments.Comment: 3 pages, 2 figures, presented at NuInt07, Fermilab, may 31 - june 3 200

Experimental Test of the Dynamical Coulomb Blockade Theory for Short Coherent Conductors

We observed the recently predicted quantum suppression of dynamical Coulomb blockade on short coherent conductors by measuring the conductance of a quantum point contact embedded in a tunable on-chip circuit. Taking advantage of the circuit modularity we measured most parameters used by the theory. This allowed us to perform a reliable and quantitative experimental test of the theory. Dynamical Coulomb blockade corrections, probed up to the second conductance plateau of the quantum point contact, are found to be accurately normalized by the same Fano factor as quantum shot noise, in excellent agreement with the theoretical predictions.Comment: 4 pages, 4 figures, accepted for publication in Physical Review Letter

Distance as a barrier to cancer diagnosis and treatment: Review of the literature

The burden of travel from a patient’s residence to health care providers is an important issue that can influence access to diagnosis and treatment ofcancer.Although several studies have shown that the travel burden can result in delays in diagnosis and treatment of many common cancers, its role appears underestimated in the treatment of patients in clinical practice. Therefore, we performed a review of the published data on the role of travel burden influencing four items: delay of diagnosis, adequate treatment of cancer, outcome, and quality of life of cancer patients. Forty-seven studies published up to December 2014 were initially identified. Twenty studies were excluded because they did not regard specifically the four items of our review.Twenty-seven studies formed the basis of our study and involved 716,153 patients. The associations between travel burden and (a) cancer stage at diagnosis (12 studies), (b) appropriate treatment (8 studies), (c) outcome (4 studies), and (d) quality of life (1 study) are reported. In addition, in two studies,therelationbetween travel burden and compliance with treatment was examined. The results of our review show that increasing travel requirements are associated with more advanced disease at diagnosis, inappropriatetreatment, aworse prognosis, and a worse quality of life. These results suggest that clinical oncologists should remember the specific travel burden problem for cancer patients, who often need health care services every week or every month for many years

DNA fragmentation in some organs of rats and mice treated with cycasin.

Cycasin (methylazoxymethanol-beta-D-glucoside) is carcinogenic in several animal species. It produces a variety of malignant tumours, mainly in the liver of mice, and in the liver, kidney and large intestine in rats. It does not appear to be mutagenic in the Ames test, even in the presence of liver microsome fraction, and it is among those carcinogens (less than 10%) ranked as "false negatives" in this test. The ability of cycasin to damage in vivo liver, kidney, lung and colonic DNA of Wistar rats and C57BL/L mice was investigated by means of alkaline elution technique. Oral single-dose administration of cycasin, in the range of 50-400 mg/kg body weight, produced in the rat a clearly evident dose-dependent DNA fragmentation in the liver, and less marked damage to DNA from kidney and colon mucosa. In mice, the same treatment produced dose-dependent DNA damage only in the liver. DNA repair up to 18 h appeared to be incomplete both in mice and rats. Methylazoxymethanol acetate is considered to be an active form of cycasin. While in vivo methylazoxymethanol acetate caused DNA damage, in vitro it appeared inactive and required metabolic activation, possibly consisting in its hydrolysis by esterase activity, to be able to cause DNA fragmentation

Role of image-guided fine-needle aspiration biopsy in the management of patients with splenic metastasis

BACKGROUND: Splenic metastases are very rare and are mostly diagnosed at the terminal phase of the disease or at the time of autopsy. The cytohistological diagnosis, when done, is made prevalently by splenectomy. Reports on splenic percutaneous biopsies in the diagnosis of splenic metastasis are fragmentary and very poor. The aims of this study are to analyse retrospectively the accuracy, safety and the clinical impact of ultrasound (US)-guided fine-needle aspiration biopsy (UG-FNAB) in patients with suspected splenic metastasis. METHODS: A retrospective analysis of 1800 percutaneous abdominal biopsies performed at our institute during the period from 1993 to 2003 was done and 160 patients that underwent splenic biopsy were found. Among these 160 patients, 12 cases with the final diagnosis of solitary splenic metastases were encountered and they form the basis of this report. The biopsies were performed under US guidance using a 22-gauge Chiba needle. All the patients underwent laboratory tests, CT examination of the abdomen and chest, US examination of abdomen and pelvis. RESULTS: There were 5 women and 7 men, median age 65 years (range 48–80). Eight patients had a known primary cancer at the time of the diagnosis of splenic metastasis: 3 had breast adenocarcinoma, 2 colon adenocarcinoma, 2 melanoma and 1 lung adenocarcinoma. Four patients were undiagnosed at the time of the appearance of splenic metastasis and subsequent investigations showed adenocarcinoma of the lung in 2 patients and colon adenocarcinoma in the remaining 2. There was a complete correspondence between the US and Computed Tomography (CT) in detecting focal lesions of the spleen. The splenic biopsies allowed a cytological diagnosis of splenic metastasis in all the 12 patients and changed clinical management in all cases. Reviewing the 160 patients that underwent UG-FNAB of the spleen we found no complications related to the biopsies. CONCLUSION: These results indicate that UG-FNAB is a successful technique for diagnosis of splenic metastasis allowing an adequate treatment of the affected patients

Targeted photoimmunotherapy for cancer

Photodynamic therapy (PDT) is a clinically approved procedure that can exert a curative action against malignant cells. The treatment implies the administration of a photoactive molecular species that, upon absorption of visible or near infrared light, sensitizes the formation of reactive oxygen species. These species are cytotoxic and lead to tumor cell death, damage vasculature, and induce inflammation. Clinical investigations demonstrated that PDT is curative and does not compromise other treatment options. One of the major limitations of the original method was the low selectivity of the photoactive compounds for malignant over healthy tissues. The development of conjugates with antibodies has endowed photosensitizing molecules with targeting capability, so that the compounds are delivered with unprecedented precision to the site of action. Given their fluorescence emission capability, these supramolecular species are intrinsically theranostic agents

Human herpesvirus 8-associated primary effusion lymphoma in human immunodeficiency virus-negative patients: a clinico-epidemiologic variant resembling classic Kaposi's sarcoma

No abstract availabl

WARP: a WIMP double phase Argon detector

The WARP programme for dark matter search with a double phase argon detector is presented. In such a detector both excitation and ionization produced by an impinging particle are evaluated by the contemporary measurement of primary scintillation and secondary (proportional) light signal, this latter being produced by extracting and accelerating ionization electrons in the gas phase. The proposed technique, verified on a 2.3 liters prototype, could be used to efficiently discriminate nuclear recoils, induced by WIMP's interactions, and measure their energy spectrum. An overview of the 2.3 liters results and of the proposed 100 liters detector is shown.Comment: Proceeding for IDM200

Progress of the Felsenkeller shallow-underground accelerator for nuclear astrophysics

Low-background experiments with stable ion beams are an important tool for putting the model of stellar hydrogen, helium, and carbon burning on a solid experimental foundation. The pioneering work in this regard has been done by the LUNA collaboration at Gran Sasso, using a 0.4 MV accelerator. In the present contribution, the status of the project for a higher-energy underground accelerator is reviewed. Two tunnels of the Felsenkeller underground site in Dresden, Germany, are currently being refurbished for the installation of a 5 MV high-current Pelletron accelerator. Construction work is on schedule and expected to complete in August 2017. The accelerator will provide intense, 50 uA, beams of 1H+, 4He+, and 12C+ ions, enabling research on astrophysically relevant nuclear reactions with unprecedented sensitivity.Comment: Submitted to the Proceedings of Nuclei in the Cosmos XIV, 19-24 June 2016, Niigata/Japa